The Impact of Influenza on Health-Related Quality of Life, Work Productivity, and Activity Impairment Among Symptomatic US Patients with Influenza Authors: Tianyan Hu, Laura L. Lupton, Alon Yehoshua, Joseph C. Cappelleri, Meghan B. Gavaghan, Verna L. Welch, Santiago M. C. Lopez, Rachel Brathwaite, Manuela Di Fusco, Xiaowu Sun Published: 2026 ABSTRACT IntroductionEvidence on the impact of influenza on health-related quality of life (HRQoL) and work productivity and activity impairment (WPAI) remains limited. This study evaluated changes in the EuroQol Visual Analogue Scale (EQ-VAS), EuroQol Utility Index (EQ-UI), absenteeism, presenteeism, work productivity loss, and activity impairment over 1 month during the high-severity 2024–2025 influenza season in the USA.MethodsSymptomatic adults (≥ 18 years) with a positive influenza test at ambulatory care clinics within a national US retail pharmacy chain (10/24/2024–4/15/2025) and symptom onset ≤ 4 days of positive test were included. HRQoL was assessed on days 1–7, 10, 14, and week 4 and WPAI on days 1, 7, 14, and week 4. Mixed models for repeated measures estimated mean changes and standard error (SE) from baseline, adjusting for relevant covariates.ResultsThe analysis included 724 adults (mean [standard deviation (SD)] age: 42.0 [13.0] years; 74.2% female). HRQoL declined following infection: EQ-VAS decreased by 26.6 points (SE 0.9) on day 1 (p < 0.001) and 3.8 (0.8) on day 10 (p < 0.001), while EQ-UI scores decreased by 0.20 (0.01) on day 1 (p < 0.001) and 0.02 (0.01) on day 7 (p < 0.001). Compared with baseline, absenteeism rose by 58.3% (1.9) on day 1 and 34.9% (1.9) on day 7 (p < 0.001); presenteeism increased by 59.2% (2.0), 43.2% (2.0), and 8.8% (1.7) on days 1, 7, and 14 respectively (p < 0.001). Work productivity loss rose by 76.3% (1.7) on day 1, 55.5% (2.1) on day 7, and 8.1% (1.8) on day 14 (p < 0.001). Activity impairment increased by 62.6% (1.6) on Day 1, 43.6% (1.8) on day 7, and 6.6% (1.6) on day 14 (p < 0.001).ConclusionsInfluenza was associated with marked declines in HRQoL, productivity, and daily functioning in symptomatic outpatients, highlighting the importance of patient-reported outcomes in capturing influenza’s real-world burden.Trial RegistrationClinicalTrials.gov identifier.Graphical Abstract available for this article.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s40121-026-01407-3. Key Summary Points Why carry out this study?Influenza affects millions each year, leading not only to significant illness, but also wider impacts on daily functioning, productivity, and overall wellbeing.Real-world evidence remains limited in quantifying the duration and magnitude of influenza’s impact on overall health, work productivity, and daily functioning, particularly during severe influenza seasons such as 2024–2025, and in high-risk groups.This study assessed how influenza affects quality of life, work productivity, and normal nonwork activities over the 1 month following infection, overall, and in high-risk groups.What was learned from the study?Influenza infection was associated with sharp decreases in health status and large increases in work time lost, reduced work performance, and limitations in daily activities peaking in the first week and improving by 2 weeks.High-risk adults experienced slower improvements in overall health status, underscoring greater burden in vulnerable populations. Why carry out this study?Influenza affects millions each year, leading not only to significant illness, but also wider impacts on daily functioning, productivity, and overall wellbeing.Real-world evidence remains limited in quantifying the duration and magnitude of influenza’s impact on overall health, work productivity, and daily functioning, particularly during severe influenza seasons such as 2024–2025, and in high-risk groups.This study assessed how influenza affects quality of life, work productivity, and normal nonwork activities over the 1 month following infection, overall, and in high-risk groups.What was learned from the study?Influenza infection was associated with sharp decreases in health status and large increases in work time lost, reduced work performance, and limitations in daily activities peaking in the first week and improving by 2 weeks.High-risk adults experienced slower improvements in overall health status, underscoring greater burden in vulnerable populations. Digital Features This article is published with digital features, including a graphical abstract to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.32755713 Introduction Globally, influenza remains one of the most prevalent infectious respiratory conditions, infecting up to 1 billion people each year between 2010 and 2024 [1]. Influenza affects millions of people annually in the USA, including an estimated 120,000–710,000 severe cases requiring hospitalization, and between 6300 and 52,000 deaths each year [2]. For the 2024–2025 influenza season, the U.S. Centers for Disease Control and Prevention (CDC) classified the severity as high on the basis of influenza mortality rates, influenza-related hospitalization rates, and influenza-like illnesses [3]. Consequently, even individuals in overall good health may experience considerable physical symptoms—such as tiredness, pain, and respiratory difficulties [1, 4]. These symptoms, even when recovery is not prolonged or complicated, can temporarily and substantially impair health-related quality of life (HRQoL) [5–9]. Influenza also disrupts daily functioning and contributes to lost productivity, characterized by absenteeism (time missed from work), presenteeism (working while ill), and activity impairment (limitations in nonwork activities) [10–13]. Despite growing literature on influenza and productivity [11], most studies have been cross-sectional, based on self-reported influenza-like illness rather than laboratory-confirmed cases, and limited to single time points [10]. Longitudinal real-world data on HRQoL and work productivity and activity impairment (WPAI) in USA outpatient settings remain scarce, particularly among high-risk subgroups with comorbidities [10, 11]. Previous analyses have shown that patients with influenza experience substantial impairments in HRQoL and WPAI within the first week of illness [14, 15], consistent with marked symptom burden during the same period [16, 17]. Moreover, recent findings from the same cohort showed that symptom burden did not fully resolve at the end of 1 month due to the persistence of mild-to-moderate symptoms [18]. Ongoing symptom burden beyond the acute phase may translate into prolonged reductions in HRQoL and WPAI. However, the extent to which these impacts persist beyond the initial week remains unclear, underscoring the need to examine longer-term effects. Quantifying influenza’s real-world impact on HRQoL and WPAI during a high-severity season provides critical insight into the patient experience and societal burden. A 1-month prospective follow-up captures both the duration of impairment and return to preinfection baseline. This study objective was to assess changes in HRQoL and WPAI over a 4-week period following test-confirmed influenza infection among US adults in the outpatient setting, including clinical high-risk groups. Methods Study Design and Participants This was a prospective, noninterventional, repeated-measures study conducted during the 2024–2025 US influenza season (ClinicalTrials.gov identifier: NCT05160636). Adults with a positive influenza test at ambulatory care clinic sites in a US national retail pharmacy chain were identified. Within 48 h of the study team receiving the results, individuals were emailed an invitation to participate. Participants were required to meet all of the following criteria: (1) age ≥ 18 years; (2) ≥ 1 self-reported symptom on the screening questionnaire; (3) symptom onset 0–4 days before the positive test; (4) a positive test from rapid influenza diagnostic tests or rapid molecular assays for influenza infection; (5) provided electronic informed consent; (6) able to complete questionnaires in English; and 7) access to the internet and to a compatible device. Exclusion criteria included: (1) no symptoms at screening; (2) influenza vaccine within 14 days of symptom onset; or (3) prior test-confirmed influenza within 30 days of completing screening. Supplementary Fig. S1 in the electronic supplementary material shows the participant flow. Participant demographic and clinical characteristics are presented in Table 1.Table 1Baseline characteristicsOverall sample (N = 724)Influenza high-riskc population (all ages) (N = 225)Employed group (N = 593)Employed high-riskc group (N = 168)Age, years, mean (SD)42.0 (13.0)47.2 (14.6)40.8 (11.9)43.8 (12.9)Self-reported sex, n (%)Female537 (74.2)168 (74.7)438 (73.9)125 (74.4)Male187 (25.8)57 (25.3)155 (26.1)43 (25.6)Race/Ethnicity, n (%)White586 (80.9)191 (84.9)470 (79.3)138 (82.1)Black or African American35 (4.8)9 (4.0)33 (5.6)9 (5.4)Hispanic or Latino52 (7.2)15 (6.7)44 (7.4)13 (7.7)Asian24 (3.3)3 (1.3)23 (3.9)2 (1.2)Other27 (3.7)7 (3.1)23 (3.9)6 (3.6)US Region of residence, n (%)Northeast128 (17.7)43 (19.1)99 (16.7)31 (18.5)South338 (46.7)101 (44.9)282 (47.6)80 (47.6)Midwest221 (30.5)70 (31.1)183 (30.9)49 (29.2)West33 (4.6)10 (4.4)26 (4.4)7 (4.2)Other/Unknown4 (0.6)1 (0.4)3 (0.5)1 (0.6)Employment status, n (%)Yes593 (81.9)168 (74.7)593 (100.0)168 (100.0)Social Vulnerability Index (SVI) a, mean (SD)0.32 (0.19)0.33 (0.19)0.33 (0.19)0.34 (0.19)SVI categorya, n (%) < 0.25315 (43.5)91 (40.4)254 (42.8)66 (39.3) ≥ 0.25 and < 0.5293 (40.5)96 (42.7)241 (40.6)73 (43.5) ≥ 0.5 and < 0.7590 (12.4)29 (12.9)74 (12.5)21 (12.5) ≥ 0.7525 (3.5)8 (3.6)24 (4.0)8 (4.8)Missing1100Antiviral useb, n (%)616 (85.1)193 (85.8)502 (84.7)144 (85.7)Received the 2024–2025 influenza vaccine, n (%)357 (49.3)122 (54.2)290 (48.9)83 (49.4)Pregnant, n (%)No520 (71.8)145 (64.4)432 (72.8)117 (69.6)Yes9 (1.2)9 (4.0)7 (1.2)7 (4.2)Not applicable195 (26.9)71 (31.6)154 (26.0)44 (26.2)Underlying health conditions, n (%)Any current/active cancers or malignancies (other than skin cancer)5 (0.7)5 (2.2)4 (0.7)4 (2.4)Cerebrovascular disease8 (1.1)8 (3.6)6 (1.0)6 (3.6)Chronic kidney disease3 (0.4)3 (1.3)1 (0.2)1 (0.6)Chronic lung conditions51 (7.0)51 (22.7)36 (6.1)36 (21.4)Chronic liver disease11 (1.5)11 (4.9)9 (1.5)9 (5.4)Endocrine disorders33 (4.6)33 (14.7)27 (4.6)27 (16.1)Heart conditions21 (2.9)21 (9.3)14 (2.4)14 (8.3)Obesity: BMI > 40104 (14.4)104 (46.2)87 (14.7)87 (51.8)Weakened immune system/ immunocompromised17 (2.3)17 (7.6)13 (2.2)13 (7.7)Blood disorders5 (0.7)5 (2.2)3 (0.5)3 (1.8)Active tuberculosis0 (0.0)0 (0.0)0 (0.0)0 (0.0)Number of comorbidities, mean (SD)0.36 (0.66)1.15 (0.69)0.34 (0.63)1.19 (0.63) ≥ 1 comorbidity, n (%)200 (27.6)200 (88.9)158 (26.6)158 (94.0) ≥ 1 comorbidity or pregnant, n (%)208 (28.7)208 (92.4)164 (27.7)164 (97.6)SD standard deviation, US United States, BMI body mass indexaSVI is a score that ranges from 0 to 1. Higher values correspond to higher vulnerabilitybAntiviral medications used included oseltamivir phosphate (Tamiflu®), baloxavir marboxil (Xofluza®), zanamivir (Relenza®), or other antiviral medicationscClinical high-risk criteria for influenza (defined as adults aged ≥ 65 years and adults < 65 years with ≥ 1 CDC-recognized underlying health condition associated with increased risk of influenza complications Table 1Baseline characteristicsOverall sample (N = 724)Influenza high-riskc population (all ages) (N = 225)Employed group (N = 593)Employed high-riskc group (N = 168)Age, years, mean (SD)42.0 (13.0)47.2 (14.6)40.8 (11.9)43.8 (12.9)Self-reported sex, n (%)Female537 (74.2)168 (74.7)438 (73.9)125 (74.4)Male187 (25.8)57 (25.3)155 (26.1)43 (25.6)Race/Ethnicity, n (%)White586 (80.9)191 (84.9)470 (79.3)138 (82.1)Black or African American35 (4.8)9 (4.0)33 (5.6)9 (5.4)Hispanic or Latino52 (7.2)15 (6.7)44 (7.4)13 (7.7)Asian24 (3.3)3 (1.3)23 (3.9)2 (1.2)Other27 (3.7)7 (3.1)23 (3.9)6 (3.6)US Region of residence, n (%)Northeast128 (17.7)43 (19.1)99 (16.7)31 (18.5)South338 (46.7)101 (44.9)282 (47.6)80 (47.6)Midwest221 (30.5)70 (31.1)183 (30.9)49 (29.2)West33 (4.6)10 (4.4)26 (4.4)7 (4.2)Other/Unknown4 (0.6)1 (0.4)3 (0.5)1 (0.6)Employment status, n (%)Yes593 (81.9)168 (74.7)593 (100.0)168 (100.0)Social Vulnerability Index (SVI) a, mean (SD)0.32 (0.19)0.33 (0.19)0.33 (0.19)0.34 (0.19)SVI categorya, n (%) < 0.25315 (43.5)91 (40.4)254 (42.8)66 (39.3) ≥ 0.25 and < 0.5293 (40.5)96 (42.7)241 (40.6)73 (43.5) ≥ 0.5 and < 0.7590 (12.4)29 (12.9)74 (12.5)21 (12.5) ≥ 0.7525 (3.5)8 (3.6)24 (4.0)8 (4.8)Missing1100Antiviral useb, n (%)616 (85.1)193 (85.8)502 (84.7)144 (85.7)Received the 2024–2025 influenza vaccine, n (%)357 (49.3)122 (54.2)290 (48.9)83 (49.4)Pregnant, n (%)No520 (71.8)145 (64.4)432 (72.8)117 (69.6)Yes9 (1.2)9 (4.0)7 (1.2)7 (4.2)Not applicable195 (26.9)71 (31.6)154 (26.0)44 (26.2)Underlying health conditions, n (%)Any current/active cancers or malignancies (other than skin cancer)5 (0.7)5 (2.2)4 (0.7)4 (2.4)Cerebrovascular disease8 (1.1)8 (3.6)6 (1.0)6 (3.6)Chronic kidney disease3 (0.4)3 (1.3)1 (0.2)1 (0.6)Chronic lung conditions51 (7.0)51 (22.7)36 (6.1)36 (21.4)Chronic liver disease11 (1.5)11 (4.9)9 (1.5)9 (5.4)Endocrine disorders33 (4.6)33 (14.7)27 (4.6)27 (16.1)Heart conditions21 (2.9)21 (9.3)14 (2.4)14 (8.3)Obesity: BMI > 40104 (14.4)104 (46.2)87 (14.7)87 (51.8)Weakened immune system/ immunocompromised17 (2.3)17 (7.6)13 (2.2)13 (7.7)Blood disorders5 (0.7)5 (2.2)3 (0.5)3 (1.8)Active tuberculosis0 (0.0)0 (0.0)0 (0.0)0 (0.0)Number of comorbidities, mean (SD)0.36 (0.66)1.15 (0.69)0.34 (0.63)1.19 (0.63) ≥ 1 comorbidity, n (%)200 (27.6)200 (88.9)158 (26.6)158 (94.0) ≥ 1 comorbidity or pregnant, n (%)208 (28.7)208 (92.4)164 (27.7)164 (97.6)SD standard deviation, US United States, BMI body mass indexaSVI is a score that ranges from 0 to 1. Higher values correspond to higher vulnerabilitybAntiviral medications used included oseltamivir phosphate (Tamiflu®), baloxavir marboxil (Xofluza®), zanamivir (Relenza®), or other antiviral medicationscClinical high-risk criteria for influenza (defined as adults aged ≥ 65 years and adults < 65 years with ≥ 1 CDC-recognized underlying health condition associated with increased risk of influenza complications Baseline characteristics SD standard deviation, US United States, BMI body mass index aSVI is a score that ranges from 0 to 1. Higher values correspond to higher vulnerability bAntiviral medications used included oseltamivir phosphate (Tamiflu®), baloxavir marboxil (Xofluza®), zanamivir (Relenza®), or other antiviral medications cClinical high-risk criteria for influenza (defined as adults aged ≥ 65 years and adults < 65 years with ≥ 1 CDC-recognized underlying health condition associated with increased risk of influenza complications Symptom Assessment Participants reported the presence and severity of 12 influenza symptoms (See Supplementary Methods in the electronic supplementary material). These symptom data were not analyzed in this manuscript. However, findings from a companion paper [18] are referenced to contextualize HRQoL and WPAI change, given that acute and persistent symptoms can influence perceived quality of life and functioning [5–13]. Patient-Reported Outcomes Health-Related Quality of Life HRQoL was assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire [19]. Responses were converted into a Utility Index (EQ-UI) using the US-based weights [19]. The EQ visual analogue scale (EQ-VAS) measured overall health using a 101-point scale from 0 = “worst imaginable health state” to 100 = “best imaginable health state” [20]. On day 1, participants completed a modified past-tense version to retrospectively assess preinfluenza baseline HRQoL and the standard present-tense version to assess current HRQoL. EQ-UI and EQ-VAS were collected on days 1–7, 10, 14, and week 4. Lower scores indicate worse HRQoL. Work Productivity and Activity Impairment Work productivity and activity impairment were assessed using the Work Productivity and Activity Impairment General Health (WPAI:GH) v2.0 questionnaire [21, 22]. The WPAI includes four domains: absenteeism (percentage of work time missed), presenteeism (impairment while working), overall work productivity loss (combined absenteeism and presenteeism), and activity impairment (impairment in nonwork activities). Scores range from 0% = no impairment to 100% = complete impairment. On day 1, participants completed two versions: a past-tense version capturing the 7 days prior to symptom onset and a present-tense version capturing time since symptom onset (excluding the current day). WPAI was collected again on days 7, 14, and week 4. Only employed participants were included in the work productivity analyses. Statistical Analysis Baseline characteristics and outcomes were summarized using descriptive statistics. Continuous variables were summarized using means and standard deviations (SD), while categorical variables were summarized using counts and percentages. Mixed models for repeated measures (MMRM) estimated longitudinal changes in HRQoL and WPAI [23]. Models included time (categorical), clinical high-risk status, self-reported sex, race/ethnicity, region, SVI, antiviral use, influenza vaccination, baseline outcome score, with interaction terms of time and clinical high-risk, as well as time and influenza vaccination, with unstructured correlation matrix for repeated measures. For each MMRM, least-squares estimates (LSE) and standard errors (SE) were calculated for means of continuous outcome scores for each time point of assessment and mean changes from prior to infection (baseline). Model-based t-tests assessed whether mean changes from baseline differed significantly from zero. P-values < 0.05 were considered statistically significant. Baseline values were reported as mean (SD), whereas changes from baseline were reported as mean (SE). The following graphs were plotted over time: 1) LSE mean EQ-VAS and EQ-UI scores; 2) LSE of mean changes in EQ-VAS and EQ-UI at each assessment day from baseline through week 4; 3) the LSE means for absenteeism, presenteeism, work productivity loss, and activity impairment scores; and 4) the LSE of mean changes in absenteeism, presenteeism, work productivity loss, and activity impairment scores at each assessment day from baseline through week 4, providing a visual summary of trends across the 1-month period. The within-cohort effect size (ES) (Cohen’s d) [24, 25] was determined by estimating the mean change from prior to infection to follow-up. The SD of change scores were used as the denominator for within-group ES, to reflect variability in individual change [26]. Effect sizes were interpreted using Cohen’s (1988) conventions, with values of 0.2–0.5 considered small, > 0.5–0.8 considered medium, and > 0.8 considered large [24, 26]. All analyses were conducted in SAS Version 9.4 (SAS Institute, Cary, NC). Missing data were not imputed. EQ-5D-5L scoring followed user-guide recommendations [20]. STROBE reporting guidelines for cohort studies were applied [27]. Subgroup Analyses Subgroup analyses evaluated changes in three high-risk groups: 1) adults ≥ 65 years and/or adults < 65 years with ≥ 1 CDC-recognized underlying health condition associated with increased risk of influenza complications [28]; 2) a subset of clinically high-risk adults which included only < 65 years to isolate comorbidity effects; 3) given the overlapping respiratory risk profiles [29, 30], a group meeting CDC criteria for high-risk of coronavirus disease 2019 (COVID-19) complications. Detailed subgroup analyses are available in the Supplementary Methods in the electronic supplementary material. Ethical Approval The study was conducted according to the guidelines of the Declaration of Helsinki. The protocol, amendments, and informed consent documents were reviewed and approved by the Sterling Institutional Review Board (Sterling IRB), an independent ethics committee based in Atlanta, Georgia, USA (Protocol #C4591034). The study complied with regulatory requirements, and followed International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Good Practices for Outcomes Research [31], and Good Pharmacoepidemiology Practice [32]. Participation in the study was voluntary and anonymous. Consent was obtained from all subjects involved in the study electronically via the study’s E-Consent platform. Participants were informed that their deidentified survey responses would be used for research purposes and may be published and of their right to refuse or withdraw from the study at any time. Participants were compensated for their time and effort. Results Baseline Demographics A total of 724 participants were included in the final analysis after validity checks. The mean (SD) age was 42.0 (13.0) years, and 74.2% were female (Table 1). Most were White (80.9%) and lived in the South or Midwest and in less vulnerable communities (mean SVI = 0.32). Influenza vaccination rates were 49.3%; uptake was modestly higher among the influenza high-risk group (54.2%), and similar among employed high-risk individuals (49.4%). Antiviral treatment rates were 85.1%. Common comorbidities included obesity (14.4%), chronic lung conditions (7.0%), and endocrine disorders (4.6%); additionally, 2.3% of participants were immunocompromised, and 1.2% were pregnant. Of the total sample, 593 participants (81.9%) were employed and included in work productivity analyses. Their characteristics mirrored the overall cohort (mean age 40.8 [11.9] years; 73.9% female; 79.3% White; mean SVI = 0.33; influenza vaccination 48.9%; antiviral treatment 84.7%; obesity 14.7%; chronic lung conditions 6.1%; endocrine disorders (4.6%) (Table 1). Data completeness was high across outcome measures. Completeness exceeded 98% for HRQoL outcomes and > 90% for most WPAI measures across time points, with exact sample sizes reported in Tables 2 and 3.Table 2Summary of least square estimates of mean change in health-related quality of life measures from prior to infection among influenza-infected adultsEQ-VASEQ-UIAll participants, NEQ-VAS available data, nLSE (SE)aESbEQ-UI available data, nLSE (SE)aESbPrior to infection c72471989.6 (7.8)7240.95 (0.07)Day 1724719−26.6 (0.9)d−1.52724−0.20 (0.01)d−0.98Day 2611604−19.1 (0.9)d−1.25611−0.14 (0.01)d−0.92Day 3604598−14.0 (0.8)d−1.04604−0.10 (0.01)d−0.67Day 4586582−10.8 (0.8)d−0.88586−0.07 (0.01)d−0.54Day 5576571−8.5 (0.8)d−0.75576−0.05 (0.01)d−0.42Day 6565562−6.8 (0.8)d−0.59565−0.04 (0.01)d−0.33Day 7562558−5.7 (0.8)d−0.53562−0.02 (0.01)d−0.24Day 10522519−3.8 (0.8)d−0.38522−0.02 (0.01)d−0.19Day 14515514−1.7 (0.7)d−0.195150.00 (0.01)−0.01Week 45005000.5 (0.7)0.065000.01 (0.01)0.08Influenza High-risk populationPrior to infection c22522488.1 (8.8)2250.94 (0.08)Day 1225224−25.6 (1.3)d−1.52225−0.21 (0.01)d−0.94Day 2195191−19.0 (1.2)d−1.25195−0.15 (0.01)d−0.84Day 3192190−14.1 (1.1)d−1.04192−0.10 (0.01)d−0.65Day 4186185−11.2 (1.1)d−0.87186−0.08 (0.01)d−0.54Day 5184183−9.5 (1.0)d−0.72184−0.07 (0.01)d−0.41Day 6180179−7.4 (1.0)d−0.58180−0.05 (0.01)d−0.37Day 7181179−6.7 (1.0)d−0.55181−0.04 (0.01)d−0.30Day 10173172−4.8 (0.9)d−0.43173−0.03 (0.01)d−0.25Day 14171171−2.6 (0.9)d−0.27171−0.01 (0.01)−0.09Week 41651650.1 (0.9)0.011650.00 (0.01)0.00EQ-VAS EuroQol visual analogue scale, EQ-UI EuroQol utility index, LSE least square estimate, SE standard error, ES effect sizeaLeast square mean estimates based on mixed models for repeated measures, which include covariates of time, high risk status, self-reported sex, race\ethnicity, region, Social Vulnerability Index, anti-viral use, receipt of influenza vaccine, baseline scores for each outcome, and interaction terms of time*high risk status, and time*receipt of influenza vaccine, with unstructured correlation matrix for repeated measuresbES refers to within-cohort effect size and was calculated as the least square estimate of mean change scores divided by the observed standard deviation of change scores from prior to infection to follow-upcMean (standard deviation) of observed scores prior to infection were reported via recall on day 1dP < 0.05Bolded LSE(SE) indicates statistically significant changes accompanied by effect sizes > the threshold for a small effectTable 3Summary of least-square estimatesa of mean change in 4 WPAI indicators from prior to infection among influenza-infected adultsEmployed, nAbsenteeismPresenteeismWork Productivity LossActivity ImpairmentAvailable data, nLSE (SE)aES bAvailable data, nLSE (SE)aES bAvailable data, nLSE (SE)aES bAvailable data, nLSE (SE)aES bAll participantsPrior to infection c5935642.4 (11.9)5605.3 (13.0)5647.3 (16.9)7247.3 (17.6)Day 159354658.3 (1.9)d1.5938459.2 (2.0)d1.9954676.3 (1.7)d2.7172462.6 (1.6)d2.04Day 746144334.9 (1.9)d1.0340443.2 (2.0)d1.4444355.5 (2.1)d1.6055843.6 (1.8)d1.29Day 144283911.6 (1.2)0.093888.8 (1.7)d0.393918.1 (1.8)d0.305156.6 (1.6)d0.27Week 4415384-0.2 (1.1)-0.013822.5 (1.5)0.153841.0 (1.6)0.055000.3 (1.5)0.01Influenza High-risk populationPrior to infection c1681643.7 (14.6)1628.0 (17.4)16411.0 (22.0)2259.7 (20.1)Day 116816162.1 (3.0)d1.6610361.6 (3.0)d2.0116178.6 (2.3)d2.6222563.2 (2.1)d1.98Day 713613238.6 (2.9)d1.0912243.6 (2.9)d1.2913257.6 (3.0)d1.4718143.2 (2.5)d1.24Day 141291143.2 (1.6)d0.141119.2 (2.3)d0.351149.9 (2.5)d0.291718.5 (2.0)d0.31Week 41181110.4 (1.4)0.021103.8 (1.8)d0.191112.8 (2.1)0.111652.3 (1.8)0.10WPAI work productivity and activity impairment, LSE least square estimate, SE standard error, ES effect sizeaLeast square mean estimates based on mixed models for repeated measures, which include covariates of time, high risk status, self-reported sex, race\ethnicity, region, Social Vulnerability Index, anti-viral use, receiving influenza vaccine, baseline scores for each outcome, and interaction terms of time*high risk status, and time*receiving influenza vaccine, with unstructured correlation matrix for repeated measuresbES refers to within-cohort effect size and was calculated as the least square estimate of mean change scores divided by the observed standard deviation of change scores from prior to infection to follow-upcMean (standard deviation) of observed scores prior to infection were reporteddP < 0.05Bolded LSE(SE) indicates statistically significant changes accompanied by effect sizes > the threshold for a small effect Table 2Summary of least square estimates of mean change in health-related quality of life measures from prior to infection among influenza-infected adultsEQ-VASEQ-UIAll participants, NEQ-VAS available data, nLSE (SE)aESbEQ-UI available data, nLSE (SE)aESbPrior to infection c72471989.6 (7.8)7240.95 (0.07)Day 1724719−26.6 (0.9)d−1.52724−0.20 (0.01)d−0.98Day 2611604−19.1 (0.9)d−1.25611−0.14 (0.01)d−0.92Day 3604598−14.0 (0.8)d−1.04604−0.10 (0.01)d−0.67Day 4586582−10.8 (0.8)d−0.88586−0.07 (0.01)d−0.54Day 5576571−8.5 (0.8)d−0.75576−0.05 (0.01)d−0.42Day 6565562−6.8 (0.8)d−0.59565−0.04 (0.01)d−0.33Day 7562558−5.7 (0.8)d−0.53562−0.02 (0.01)d−0.24Day 10522519−3.8 (0.8)d−0.38522−0.02 (0.01)d−0.19Day 14515514−1.7 (0.7)d−0.195150.00 (0.01)−0.01Week 45005000.5 (0.7)0.065000.01 (0.01)0.08Influenza High-risk populationPrior to infection c22522488.1 (8.8)2250.94 (0.08)Day 1225224−25.6 (1.3)d−1.52225−0.21 (0.01)d−0.94Day 2195191−19.0 (1.2)d−1.25195−0.15 (0.01)d−0.84Day 3192190−14.1 (1.1)d−1.04192−0.10 (0.01)d−0.65Day 4186185−11.2 (1.1)d−0.87186−0.08 (0.01)d−0.54Day 5184183−9.5 (1.0)d−0.72184−0.07 (0.01)d−0.41Day 6180179−7.4 (1.0)d−0.58180−0.05 (0.01)d−0.37Day 7181179−6.7 (1.0)d−0.55181−0.04 (0.01)d−0.30Day 10173172−4.8 (0.9)d−0.43173−0.03 (0.01)d−0.25Day 14171171−2.6 (0.9)d−0.27171−0.01 (0.01)−0.09Week 41651650.1 (0.9)0.011650.00 (0.01)0.00EQ-VAS EuroQol visual analogue scale, EQ-UI EuroQol utility index, LSE least square estimate, SE standard error, ES effect sizeaLeast square mean estimates based on mixed models for repeated measures, which include covariates of time, high risk status, self-reported sex, race\ethnicity, region, Social Vulnerability Index, anti-viral use, receipt of influenza vaccine, baseline scores for each outcome, and interaction terms of time*high risk status, and time*receipt of influenza vaccine, with unstructured correlation matrix for repeated measuresbES refers to within-cohort effect size and was calculated as the least square estimate of mean change scores divided by the observed standard deviation of change scores from prior to infection to follow-upcMean (standard deviation) of observed scores prior to infection were reported via recall on day 1dP < 0.05Bolded LSE(SE) indicates statistically significant changes accompanied by effect sizes > the threshold for a small effect Summary of least square estimates of mean change in health-related quality of life measures from prior to infection among influenza-infected adults EQ-VAS EuroQol visual analogue scale, EQ-UI EuroQol utility index, LSE least square estimate, SE standard error, ES effect size aLeast square mean estimates based on mixed models for repeated measures, which include covariates of time, high risk status, self-reported sex, race\ethnicity, region, Social Vulnerability Index, anti-viral use, receipt of influenza vaccine, baseline scores for each outcome, and interaction terms of time*high risk status, and time*receipt of influenza vaccine, with unstructured correlation matrix for repeated measures bES refers to within-cohort effect size and was calculated as the least square estimate of mean change scores divided by the observed standard deviation of change scores from prior to infection to follow-up cMean (standard deviation) of observed scores prior to infection were reported via recall on day 1 dP < 0.05 Bolded LSE(SE) indicates statistically significant changes accompanied by effect sizes > the threshold for a small effect Table 3Summary of least-square estimatesa of mean change in 4 WPAI indicators from prior to infection among influenza-infected adultsEmployed, nAbsenteeismPresenteeismWork Productivity LossActivity ImpairmentAvailable data, nLSE (SE)aES bAvailable data, nLSE (SE)aES bAvailable data, nLSE (SE)aES bAvailable data, nLSE (SE)aES bAll participantsPrior to infection c5935642.4 (11.9)5605.3 (13.0)5647.3 (16.9)7247.3 (17.6)Day 159354658.3 (1.9)d1.5938459.2 (2.0)d1.9954676.3 (1.7)d2.7172462.6 (1.6)d2.04Day 746144334.9 (1.9)d1.0340443.2 (2.0)d1.4444355.5 (2.1)d1.6055843.6 (1.8)d1.29Day 144283911.6 (1.2)0.093888.8 (1.7)d0.393918.1 (1.8)d0.305156.6 (1.6)d0.27Week 4415384-0.2 (1.1)-0.013822.5 (1.5)0.153841.0 (1.6)0.055000.3 (1.5)0.01Influenza High-risk populationPrior to infection c1681643.7 (14.6)1628.0 (17.4)16411.0 (22.0)2259.7 (20.1)Day 116816162.1 (3.0)d1.6610361.6 (3.0)d2.0116178.6 (2.3)d2.6222563.2 (2.1)d1.98Day 713613238.6 (2.9)d1.0912243.6 (2.9)d1.2913257.6 (3.0)d1.4718143.2 (2.5)d1.24Day 141291143.2 (1.6)d0.141119.2 (2.3)d0.351149.9 (2.5)d0.291718.5 (2.0)d0.31Week 41181110.4 (1.4)0.021103.8 (1.8)d0.191112.8 (2.1)0.111652.3 (1.8)0.10WPAI work productivity and activity impairment, LSE least square estimate, SE standard error, ES effect sizeaLeast square mean estimates based on mixed models for repeated measures, which include covariates of time, high risk status, self-reported sex, race\ethnicity, region, Social Vulnerability Index, anti-viral use, receiving influenza vaccine, baseline scores for each outcome, and interaction terms of time*high risk status, and time*receiving influenza vaccine, with unstructured correlation matrix for repeated measuresbES refers to within-cohort effect size and was calculated as the least square estimate of mean change scores divided by the observed standard deviation of change scores from prior to infection to follow-upcMean (standard deviation) of observed scores prior to infection were reporteddP < 0.05Bolded LSE(SE) indicates statistically significant changes accompanied by effect sizes > the threshold for a small effect Summary of least-square estimatesa of mean change in 4 WPAI indicators from prior to infection among influenza-infected adults WPAI work productivity and activity impairment, LSE least square estimate, SE standard error, ES effect size aLeast square mean estimates based on mixed models for repeated measures, which include covariates of time, high risk status, self-reported sex, race\ethnicity, region, Social Vulnerability Index, anti-viral use, receiving influenza vaccine, baseline scores for each outcome, and interaction terms of time*high risk status, and time*receiving influenza vaccine, with unstructured correlation matrix for repeated measures bES refers to within-cohort effect size and was calculated as the least square estimate of mean change scores divided by the observed standard deviation of change scores from prior to infection to follow-up cMean (standard deviation) of observed scores prior to infection were reported dP < 0.05 Bolded LSE(SE) indicates statistically significant changes accompanied by effect sizes > the threshold for a small effect Findings from MMRM: HRQoL Changes Over Time EQ-VAS scores showed substantial declines following influenza infection (Table 2; Fig. 1A–B). The baseline mean (SD) was 89.6 (7.8). On day 1, mean (SE) scores were 26.6 (0.9) points lower, improving steadily to 1.7 (0.7) points lower by day 14. Differences remained below zero through day 14 (all p-values < 0.05), at each time point (unadjusted for multiple comparisons). Within-cohort effect sizes (Cohen’s d) were large in the first 4 days (−1.52 to −0.88), medium on days 5–7 (−0.75 to −0.53), small by day 10 (−0.38) and below the threshold of small effect by day 14 (−0.19).Fig. 1LSE for: a means and b mean changes for EQ-VAS and EQ-UI over 28 days. Day -1 reflects the period prior to infection or symptom onset. EQ-VAS, EuroQol Visual Analogue Scale; EQ-UI, EuroQol Utility Index; LSE, least squares estimates LSE for: a means and b mean changes for EQ-VAS and EQ-UI over 28 days. Day -1 reflects the period prior to infection or symptom onset. EQ-VAS, EuroQol Visual Analogue Scale; EQ-UI, EuroQol Utility Index; LSE, least squares estimates EQ-UI showed a shorter duration of impact. The baseline mean (SD) was 0.95 (0.07). On day 1, mean (SE) scores were 0.20 (0.01) points lower, and on day 10 they were 0.02 (0.01) points lower (Table 2). Differences remained below zero through day 10, with p-values at < 0.05 at each time point. Within-cohort effect sizes were large on days 1–2 (−0.98; −0.92), medium on days 3–4 (−0.67; −0.54), small on day 7 (−0.24), but negligible by day 10 (−0.19). Observed EQ-VAS and EQ-UI scores are shown in Supplementary Table S1 in the electronic supplementary material; model estimates in Supplementary Table S2. Findings from MMRM: WPAI Changes Over Time Absenteeism increased sharply after influenza infection (Table 3; Fig. 2A–B). The baseline mean (SD) was 2.4% (11.9). On day 1, work time missed was 58.3% (1.9) higher and on day 7 it was 34.9% (1.9) higher, with p < 0.001 on both days. Within-cohort ESs were large on both days (1.59; 1.03). By day 14 and week 4, absenteeism had returned to baseline.Fig. 2LSE for: a means and b mean changes for WPAI:GH scores over 28 days. Day -1 reflects the period prior to infection or symptom onset. WPAI:GH, Work Productivity and Activity Impairment General Health questionnaire; LSE, least squares estimates LSE for: a means and b mean changes for WPAI:GH scores over 28 days. Day -1 reflects the period prior to infection or symptom onset. WPAI:GH, Work Productivity and Activity Impairment General Health questionnaire; LSE, least squares estimates Other WPAI domains showed more prolonged effects. Presenteeism rose from a baseline mean (SD) of 5.3% (13.0) to mean (SE) of 59.2% (2.0) higher on day 1 and 43.2% (2.0) higher on day 7 and remained 8.8% (1.7) higher on day 14, with p < 0.001 on all three days. Within-cohort ESs were large on days 1 (1.99) and 7 (1.44) and small on day 14 (0.39). Overall work impairment followed a similar trajectory: baseline mean (SD) 7.3% (16.9), with mean (SE) increases of 76.3% (1.7), 55.5% (2.1), and 8.1% (1.8) on days 1, 7, and 14 (all p-values < 0.001). Within-cohort ESs were large on days 1 (2.71) and 7 (1.60) and small on day 14 (0.30). Activity impairment also rose markedly, from a baseline mean (SD) of 7.3% (17.6), increasing by 62.6% (1.6) on day 1 and 43.6% (1.8) on day 7 and remained elevated by 6.6% (1.6) on day 14 (all p-values < 0.001). Within-cohort ESs were large on days 1 (2.04) and 7 (1.29) and small on day 14 (0.27). Observed WPAI scores are presented in Supplementary Table S3, and MMRM parameter estimates in Supplementary Table S4 in the electronic supplementary material. Subgroup Results Detailed results from subgroup analyses are available in Tables 2 and 3 and in Supplementary Tables S1–S7 in the electronic supplementary material. Across all high-risk subgroups, HRQoL and WPAI patterns were consistent with the overall sample, except that all clinically high-risk adults experienced more sustained HRQoL impairment with clinically meaningful impacts. In high-risk adults, EQ-VAS scores remained below baseline with small ES on day 14 and EQ-UI scores remained below baseline with small ES on day 10. In contrast, in the overall sample, EQ-VAS and EQ-UI were also below baseline through day 14 and day 10, respectively, but ES were < 0.20, indicating that these changes were not clinically meaningful. Although elevated levels of absenteeism were observed through day 14 and presenteeism through week 4 (Table 3), neither reached the threshold for small effects in the high-risk population. Discussion This nationwide prospective observational study conducted among symptomatic US adult outpatients with influenza showed that influenza infection was associated with substantial declines in perceived quality of life, work productivity, and nonwork activity levels. HRQoL was impaired over approximately 2 weeks, with lower EQ-VAS scores (through day 14) and lower EQ-UI scores (through day 10). Early declines were clinically meaningful, but by day 14 (EQ-VAS) and day 10 (EQ-UI), effect sizes had diminished to < 0.20, indicating negligible clinical impact. Work productivity and nonwork activity levels were also impaired due to influenza, with adults missing more days of work (absenteeism) than prior to infection over the first week (through day 7). They also experienced higher presenteeism, greater overall work impairment, and more activity impairment, persisting through day 14. Adults at high risk for influenza also experienced decreases in HRQoL, work productivity, and activity levels that were consistent with patterns observed in the overall sample. However, their HRQoL as assessed by EQ-VAS and EQ-UI persisted, remaining below baseline and meeting thresholds for clinical significance slightly longer. When referring to the companion-symptom burden analysis of this cohort [18], HRQoL and WPAI changes aligned with the symptom trajectory reported there. That analysis found that severe symptoms returned to baseline by day 6, while mild-to-moderate symptoms persisted for up to 4 weeks. This aligns with the finding in the present study that absenteeism returned to baseline by day 14, but presenteeism, work impairment, activity impairment, and HRQoL deficits extended through day 14. These findings reinforce that acute influenza symptoms are a primary driver of short-term declines in quality of life and productivity. Peak impairments in EQ-VAS, EQ-UI, absenteeism, presenteeism, overall work impairment, and activity impairment occurred during the period of highest severe symptom burden, and improvements coincided with return to baseline of severe symptoms. It is likely that lingering less severe symptoms contributed to continued functional limitations and delayed recovery through day 14. These patterns are consistent with the clinical course of influenza, where functional recovery often precedes complete symptom resolution [33, 34]. Prior research on respiratory infections similarly shows that individuals may return to work while still experiencing residual symptoms [33, 34], and that HRQoL impairment during recovery is often driven by these lingering complaints [35, 36]. Notably, in the companion symptom burden analysis, a considerable proportion of participants experienced mild cough, stuffy or runny nose, and fatigue at 2 weeks and beyond [18]. It is likely that these symptoms continued to affect daily functioning and perceived health status despite improvements in acute illness. For HRQoL, prior to infection, high mean scores on EQ-VAS and EQ-UI, signified that patients perceived themselves to be in good overall health, yet declines were observed postinfection. In the current study EQ-VAS on day 1 was 63.2, whereas prior US research reported EQ-VAS score of 48.5 at initial assessment post influenza infection [37], indicating a less severe decline in HRQoL. This may be partially attributable to different characteristics (fewer with underlying conditions), or a more recent season (2024/25 versus 2011/12–2019/20 seasons). Also, this study included participants within 4 days of illness onset compared with 3 days in the prior study, potentially capturing individuals at a later stage of illness when symptoms may have already begun to resolve [37]. However, similar declines in HRQoL have been reported in England and Spain [7, 9]. In England, EQ-VAS declined from 84.0 preinfection to 43.0 at the worst day of illness, and EQ-UI from 0.92 to 0.36 [9]. In the current study, EQ-VAS declined from 89.6 at baseline to 63.2 on day 1, and EQ-UI from 0.95 to 0.75. Differences in magnitude likely reflect timing, as this study assessed burden on day 1 of study participation capturing participants’ current health status rather than asking them to recall their worst point since illness onset, whereas the English study captured the worst day. In Spain, EQ-UI scores declined from 0.93 preinfluenza to 0.50 during infection [7], compared with 0.95 to 0.75 on day 1 in the current study’s sample. Differences are potentially due to season (2024/25 versus 2009 H1N1 pandemic season), age distribution (> 18 years versus > 8 years), and fewer comorbidities (27.5% versus 37.3%). Together, these findings support that influenza is associated with a temporal impact on HRQoL, although the magnitude may vary across populations, seasons, time since infection, and healthcare contexts. For WPAI, these findings are consistent with previous influenza studies, which show adults experienced greater absence from work and reduced productivity while working [33]. Previous US research analyzed over 1200 employed adults with laboratory-confirmed influenza across four influenza seasons and found that influenza was associated with workplace productivity loss (mean loss of 67–74%) [12]. Nonetheless, slightly higher mean percent changes in work productivity loss were observed on day 1 in this study (Tables 3 and Supplementary Table S7 in the electronic supplementary material): 76.3% in the overall influenza sample, 78.6% in high-risk influenza adults, 78.6% in high-risk COVID-19 adults, and 78.8% in high-risk influenza adults < 65 years (Supplementary Table S7 in the electronic supplementary material). This study extends prior analyses by including four repeated assessments over 1 month, compared with 7–17 days of follow-up in earlier research. This longer follow-up allowed us to estimate recovery timing, showing return to baseline by day 14 or week 4 depending on subgroup. Compared with overall sample, clinically high-risk groups (high-risk subgroup, high-risk subgroup < 65 years, and influenza sample at high-risk for COVID-19) experienced longer meaningful impairment in HRQoL as measured using EQ-UI scores (day 10 versus day 7), indicating slower return to preinfection health state, as reported in the results (Tables 2 and Supplementary Table S6 in the electronic supplementary material). These findings highlight the need for targeted interventions to reduce the humanistic burden in vulnerable populations. This study has several limitations. All data were self-reported and subject to recall and selection bias with some missingness (survey drop-off). While participant characteristics remained stable through week 4 (Supplementary Table S8 in the electronic supplementary material), findings may not generalize to rural populations, more vulnerable communities, or those seeking care in other healthcare settings. The sample was predominantly White adults from certain US regions who self-selected to get tested at ambulatory care clinic sites in a US national retail pharmacy chain, possibly reflecting greater health consciousness or more severe symptoms. Attrition may have led to underestimation if participants with greater impairment were more likely to drop out (Supplementary Table S9 in the electronic supplementary material), potentially missing data from those experiencing the greatest WPAI and HRQoL impairment. Hence the estimates of recovery may be biased, toward faster resolution. Additionally, requiring English literacy and email access may introduce selection bias by excluding individuals with limited English proficiency and digital access, reducing the sociodemographic representativeness of the sample. Furthermore, compensation may have introduced bias if incentives influenced participants’ motivation or response quality. Notably, because symptom onset could occur up to 4 days before testing, the earliest phase of illness may be missed, potentially underestimating the impact on HRQoL and WPAI. Relatedly, because preinfluenza HRQoL and WPAI were assessed retrospectively at day 1, participants may over- or under- estimate the preillness status due to recall bias and response shift. There may be potential misclassification of influenza status, since the gold standard polymerase chain reaction (PCR) laboratory testing was not used. Influenza virus subtyping was unavailable, limiting assessment of whether differences in symptom severity and related impacts on quality of life, productivity, and activity impairment varied by subtype. Although vaccine-by-time interaction was adjusted for in the models, moderate influenza vaccine effectiveness during the 2024–2025 season [38], potentially influenced by vaccine-strain mismatch, may have reduced the magnitude of differences observed between vaccinated and unvaccinated participants in symptom severity and related quality of life, work productivity and activity impairment. While participants with test-confirmed influenza and COVID-19 coinfection were excluded, coinfections with other respiratory viruses were not assessed and may have influenced symptom severity and related impacts on quality of life, work productivity, and activity impairment. Despite these limitations, the study has important strengths. Participants in a large nationwide outpatient cohort were enrolled within 48 h of a positive influenza test and prospectively followed, minimizing recall bias. Validated instruments (EQ-5D-5L, WPAI:GH) were used to assess HRQoL and WPAI. Repeated measurements over 4 weeks provided detailed insight into the duration and resolution of influenza-related impairment. By capturing both HRQoL and WPAI impacts longitudinally, it offers new insights into areas that have been previously underexplored and helps fill a critical void in understanding the broader burden of influenza. Conclusion This prospective study demonstrates that influenza imposes a measurable humanistic and productivity-related impact on US adults. Symptomatic infection was associated with marked but temporary declines in HRQoL and activity levels, with recovery generally occurring within 2 weeks. Among employed adults, influenza infection was accompanied by substantial absenteeism, presenteeism, and overall productivity loss, underscoring the impact of acute respiratory illness on the workforce. Importantly, high-risk adults experienced longer recovery, highlighting the disproportionate burden carried by vulnerable groups. This research underscores the importance of patient-reported outcomes (PROs) for capturing real-world insights into the lived experience of influenza in an outpatient cohort. By systematically measuring HRQoL and WPAI in adults with a longer follow-up period, PRO research provides evidence that complements clinical outcomes, illuminates the burden of disease to patients, and the broader economy, and informs decision-making in public health and workplace policy. Collectively, these results reinforce the value of strategies aimed at preventing the burden of influenza, preserving health-related quality of life, and mitigating productivity losses, particularly in high-risk populations where recovery is slower. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 425 KB) Supplementary file1 (PDF 425 KB)